Kisunla
Active substance: donanemab
INJECTION, SOLUTION · DONANEMAB 17.5 mg/mL
United StatesActive
Marketing holder: Eli Lilly and Company
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- DONANEMAB · 17.5 mg/mL
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1209a-c0ee-7613-b5a3-2926200ca166;count=1 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 0002-9401
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- INTRAVENOUS
Sources
- product · openFDA NDC · 0002-9401 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 0002-9401 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 0002-9401 · Verified 2026-10-09 · open in source